Evaluation of immunogenicity and protective efficacy of bacteriophage conjugated haemagglutinin based subunit vaccine against equine influenza virus in a murine model.

التفاصيل البيبلوغرافية
العنوان:	Evaluation of immunogenicity and protective efficacy of bacteriophage conjugated haemagglutinin based subunit vaccine against equine influenza virus in a murine model.
المؤلفون:	Kumar R; Department of Veterinary Public Health and Epidemiology, LUVAS, Hisar, Haryana, 125004, India., Bera BC; ICAR- National Research Centre on Equines, Hisar, Haryana, 125 001, India., Anand T; ICAR- National Research Centre on Equines, Hisar, Haryana, 125 001, India., Pavulraj S; Louisiana State University School of Veterinary Medicine, Skip Bertman Dr, Baton Rouge, LA, 70803, USA., Kurian Mathew M; ICAR- National Research Centre on Equines, Hisar, Haryana, 125 001, India., Gupta RP; Department of Veterinary Pathology, LUVAS, Hisar, Haryana, 125004, India., Tripathi BN; Sher-e-Kashmir University of Agricultural Sciences and Technology, Jammu, 180009, India., Virmani N; ICAR- National Research Centre on Equines, Hisar, Haryana, 125 001, India. nvirmani@gmail.com.
المصدر:	Veterinary research communications [Vet Res Commun] 2024 Jun; Vol. 48 (3), pp. 1707-1726. Date of Electronic Publication: 2024 Mar 26.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Springer Country of Publication: Switzerland NLM ID: 8100520 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7446 (Electronic) Linking ISSN: 01657380 NLM ISO Abbreviation: Vet Res Commun Subsets: MEDLINE
أسماء مطبوعة:	Publication: [Cham] : Springer Original Publication: [Amsterdam] : Elsevier, 1980-
مواضيع طبية MeSH:	Influenza Vaccines/immunology , Orthomyxoviridae Infections/prevention & control , Orthomyxoviridae Infections/veterinary , Orthomyxoviridae Infections/immunology , Vaccines, Subunit/immunology , Influenza A Virus, H3N8 Subtype/immunology, Animals ; Mice ; Female ; Bacteriophages/immunology ; Bacteriophages/genetics ; Mice, Inbred BALB C ; Horse Diseases/prevention & control ; Horse Diseases/immunology ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Immunogenicity, Vaccine ; Horses
مستخلص:	Equine influenza (EI) is a highly contagious acute respiratory disease of equines caused by the H3N8 subtype of Influenza A virus i.e. equine influenza virus (EIV). Vaccination is an important and effective tool for the control of EI in equines. Most of the commercial influenza vaccines are produced in embryonated hen's eggs which has several inherent disadvantages. Hence, subunit vaccine based on recombinant haemagglutinin (HA) antigen, being the most important envelope glycoprotein has been extensively exploited for generating protective immune responses, against influenza A and B viruses. We hypothesized that novel vaccine formulation using baculovirus expressed recombinant HA1 (rHA1) protein coupled with bacteriophage will generate strong protective immune response against EIV. In the present study, the recombinant HA1 protein was produced in insect cells using recombinant baculovirus having cloned HA gene of EIV (Florida clade 2 sublineage) and the purified rHA1 was chemically coupled with bacteriophage using a crosslinker to produce rHA1-phage vaccine candidate. The protective efficacy of vaccine preparations of rHA1-phage conjugate and only rHA1 proteins were evaluated in mouse model through assessing serology, cytokine profiling, clinical signs, gross and histopathological changes, immunohistochemistry, and virus quantification. Immunization of vaccine preparations have stimulated moderate antibody response (ELISA titres-5760 ± 640 and 11,520 ± 1280 for rHA1 and rHA1-phage, respectively at 42 dpi) and elicited strong interferon (IFN)-γ expression levels after three immunizations of vaccine candidates. The immunized BALB/c mice were protected against challenge with wild EIV and resulted in reduced clinical signs and body weight loss, reduced pathological changes, decreased EIV antigen distribution, and restricted EIV replication in lungs and nasopharynx. In conclusion, the immune responses with moderate antibody titer and significantly higher cytokine responses generated by the rHA1-phage vaccine preparation without any adjuvant could be a novel vaccine candidate for quick vaccine preparation through further trials of vaccine in the natural host. (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
References:	Anand T, Vaid RK, Bera BC, Singh J, Barua S, Virmani N, Yadav NK, Nagar D, Singh RK, Tripathi BN (2016) Isolation of a lytic bacteriophage against virulent Aeromonas hydrophila from an organized equine farm. J Basic Microbiol 56:432–437. https://doi.org/10.1002/jobm.201500318. (PMID: 10.1002/jobm.20150031826748732) Audsley JM, Tannock GA (2004) The role of cell culture vaccines in the control of the next influenza pandemic. Exp Opin Biol Ther 4:709–717. https://doi.org/10.1517/14712598.4.5.709. (PMID: 10.1517/14712598.4.5.709) Bakhshinejad B, Sadeghizadeh M (2014) Bacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems. Exper Opin Drug Deliv 11:1561–1574. https://doi.org/10.1517/17425247.2014.927437. (PMID: 10.1517/17425247.2014.927437) Bryant NA, Rash AS, Russell CA, Ross J, Cooke A, Bowman S, MacRae S, Lewis NS, Paillot R, Zanoni R, Meier H (2009) Antigenic and genetic variations in European and north American equine influenza virus strains (H3N8) isolated from 2006 to 2007. Vet Microbiol 138:41–52. https://doi.org/10.1016/j.vetmic.2009.03.004. (PMID: 10.1016/j.vetmic.2009.03.00419346084) Chambers TM, Holland RE, Tudor LR, Townsend HG, Cook A, Bogdan J, Lunn DP, Hussey S, Whitaker-Dowling P, Youngner JS, Sebring RW (2001) A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet J 33:630–636. https://doi.org/10.2746/042516401776249291. Clark JR, March JB (2004) Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol Med Microbiol 40:21–26. https://doi.org/10.1016/S0928-8244(03)00344-4. (PMID: 10.1016/S0928-8244(03)00344-414734182) Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, Brown F (1987) Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330:381–384. https://doi.org/10.1038/330381a0. (PMID: 10.1038/330381a02446137) Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L (1991) Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. The Lancet 337:567–572. https://doi.org/10.1016/0140-6736(91)91636-9. Cox M (2005) Cell-based protein vaccines for influenza. Curr Opin Mol 7:24–29 PMID: 15732526. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: past and present. Annu Rev Med 51:407–421. https://doi.org/10.1146/annurev.med.51.1.407. (PMID: 10.1146/annurev.med.51.1.40710774473) Cox MM, Izikson R, Post P, Dunkle L (2015) Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines 3:97–108. https://doi.org/10.1177/2051013615595595. (PMID: 10.1177/2051013615595595264788174591523) Cuesta AM, Suárez E, Larsen M, Jensen KB, Sanz L, Compte M, Kristensen P, Álvarez-Vallina L (2006) Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology 117:502–506. https://doi.org/10.1111/j.1365-2567.2006.02325.x. (PMID: 10.1111/j.1365-2567.2006.02325.x165562641782252) Cullinane A, Elton D, Mumford J (2010) Equine influenza–surveillance and control. Influenza Other Respir Viruses 4:339–344. https://doi.org/10.1111/j.1750-2659.2010.00176.x. (PMID: 10.1111/j.1750-2659.2010.00176.x209589274634605) Cummings JF, Guerrero ML, Moon JE, Waterman P, Nielsen RK, Jefferson S, Gross FL, Hancock K, Katz JM, Yusibov V, Fraunhofer (2014) Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1) pdm09 virus: a phase 1 dose-escalation study in healthy adults. Vaccine 32:2251–2259. https://doi.org/10.1016/j.vaccine.2013.10.017. (PMID: 10.1016/j.vaccine.2013.10.01724126211) Daly JM, Lai AC, Binns MM, Chambers TM, Barrandeguy M, Mumford JA (1996) Antigenic and genetic evolution of equine H3N8 influenza a viruses. J Gen Virol 77:661–671. https://doi.org/10.1099/0022-1317-77-4-661. (PMID: 10.1099/0022-1317-77-4-6618627254) De Berardinis P, Sartorius R, Fanutti C, Perham RN, Del Pozzo G, Guardiola J (2000) Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat Biotechnol 18:873–876. https://doi.org/10.1038/78490. (PMID: 10.1038/7849010932158) Deng X, Li H, Tang YW (2003) Cytokine expression in respiratory syncytial virus-infected mice as measured by quantitative reverse-transcriptase PCR. J Virol Methods 107:141–146. https://doi.org/10.1016/s0166-0934(02)00211-2. (PMID: 10.1016/s0166-0934(02)00211-212505627) Elton D, Bryant N (2011) Facing the threat of equine influenza. Equine Vet J 43:250–258. https://doi.org/10.1111/j.2042-3306.2010.00357.x. (PMID: 10.1111/j.2042-3306.2010.00357.x21492200) Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L (2005) The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 23:4860–4866. https://doi.org/10.1016/j.vaccine.2005.05.024. (PMID: 10.1016/j.vaccine.2005.05.02416029917) Fougerolle S, Fortier C, Legrand L, Jourdan M, Marcillaud-Pitel C, Pronost S, Paillot R (2019) Success and limitation of equine influenza vaccination: the First Incursion in a decade of a Florida Clade 1 equine influenza virus that shakes Protection despite High Vaccine Coverage. Vaccines 7:174. https://doi.org/10.3390/vaccines7040174. (PMID: 10.3390/vaccines7040174316840976963532) Gamage LN, Ellis J, Hayes S (2009) Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes. Vaccine 27:6595–6604. https://doi.org/10.1016/j.vaccine.2009.08.019. (PMID: 10.1016/j.vaccine.2009.08.01919712770) Gao J, Wang Y, Liu Z, Wang Z (2010) Phage display and its application in vaccine design. Ann Microbiol 60:13–19. https://doi.org/10.1007/s13213-009-0014-7. (PMID: 10.1007/s13213-009-0014-7) Gaubin M, Fanutti C, Mishal Z et al (2003) Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 22:11–18. https://doi.org/10.1089/104454903321112451. (PMID: 10.1089/10445490332111245112590733) Gildea S, Quinlivan M, Arkins S, Cullinane A (2012) The molecular epidemiology of equine influenza in Ireland from 2007–2010 and its international significance. Equine Vet J 44:387–392. https://doi.org/10.1111/j.2042-3306.2011.00472.x. (PMID: 10.1111/j.2042-3306.2011.00472.x21978127) Gildea S, Quinlivan M, Murphy BA, Cullinane A (2013) Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings - a blinded comparison of commercially available vaccines. Vaccine 31:5216–5222. https://doi.org/10.1016/j.vaccine.2013.08.083. (PMID: 10.1016/j.vaccine.2013.08.08324021309) Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T (2012) Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza a virus challenge. PLoS ONE 7:45765. https://doi.org/10.1371/journal.pone.0045765. (PMID: 10.1371/journal.pone.0045765) Hernandez LA, Miller CL, Vaughn EM (2016) Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs. Vet Microbiol 191:35–43. https://doi.org/10.1016/j.vetmic.2016.05.011. (PMID: 10.1016/j.vetmic.2016.05.01127374905) Hitchman RB, Possee RD, King LA (2009) Baculovirus expression systems for recombinant protein production in insect cells. Recent Pat Biotechnol 3:46–54. https://doi.org/10.2174/187220809787172669. (PMID: 10.2174/18722080978717266919149722) Ismaila Shittu CA, Meseko LP, Sulaiman B, Inuwa M, Mustapha PS, Zakariya, Aliyu A, Muhammad U, Muhammad YJ, Atuman IJ, Barde B, Zecchin EG, Quaranta D, Shamaki O, Alabi I, Monne A, Fusaro, Tony M, Joannis (2020) Fatal multiple outbreaks of equine influenza H3N8 in Nigeria, 2019: the first introduction of Florida clade 1 to West Africa. Vet Microbiol 248:108820. https://doi.org/10.1016/j.vetmic.2020.108820. (PMID: 10.1016/j.vetmic.2020.10882032891950) Jepson CD, March JB (2004) Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine 22:2413–2419. https://doi.org/10.1016/j.vaccine.2003.11.065. (PMID: 10.1016/j.vaccine.2003.11.06515193403) Karamendin K, Kydyrmanov A, Kasymbekov Y, Khan E, Daulbayeva K, Asanova S, Zhumatov K, Seidalina A, Sayatov M, Fereidouni SR (2014) Continuing evolution of equine influenza virus in Central Asia, 2007–2012. Arch Virol 159:2321–2327. https://doi.org/10.1007/s00705-014-2078-3. (PMID: 10.1007/s00705-014-2078-324748052) Kumar R, Gupta RP, Bera BC, Anand T, Bhatia S, Kumar N, Sood R, Pavulraj S, Mathew MK, Balena V, Karthik S (2020) Pathological and immunological protection induced by inactivated reverse genetics-based H3N8 equine influenza vaccine candidate in murine model. Acta Virol 64:359–374. https://doi.org/10.4149/av_2020_314. (PMID: 10.4149/av_2020_31432985215) Lu Z, Chambers TM, Boliar S, Branscum AJ, Sturgill TL, Timoney PJ, Reedy SE, Tudor LR, Dubovi EJ, Vickers ML, Sells S (2009) Development and evaluation of one-step TaqMan real-time reverse transcription-PCR assays targeting nucleoprotein, matrix, and hemagglutinin genes of equine influenza virus. JCM 47:3907–3913. https://doi.org/10.1128/JCM.00598-09. (PMID: 10.1128/JCM.00598-09) Luna LG (1968) Manual of histologic staining methods of the Armed. Forces Institute of Pathology. Mallajosyula JK, Hiatt E, Hume S, Johnson A, Jeevan T, Chikwamba R, Pogue GP, Bratcher B, Haydon H, Webby RJ, McCormick AA (2014) Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. Hum Vaccin Immunother 10:586–595. https://doi.org/10.4161/hv.27567. (PMID: 10.4161/hv.2756724378714) Masic A, Pyo HM, Babiuk S, Zhou Y (2013) An eight-segment swine influenza virus harbouring H1 and H3 hemagglutinins is attenuated and protective against H1N1 and H3N2 subtypes in pigs. J Virol 87:10114–10125. https://doi.org/10.1128/JVI.01348-13. (PMID: 10.1128/JVI.01348-13238436333753983) Mathew MK, Virmani N, Bera BC, Anand T, Kumar R, Balena V, Sansanwal R, Pavulraj S, Sundaram K, Virmani M, Tripathi BN (2019) Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with MontanideTM Pet Gel in murine model. J Vet Med Sci 19–0399. https://doi.org/10.1292/jvms.19-0399. Na HN, Kim KH, Song MK, Park HL, Lee EY, Shim SH, Park S, Nam JH (2013) Immunogenicity and safety of H1 N 1 influenza hemagglutinin protein expressed in a baculovirus system. Microbiol Immunol 57:660–664. https://doi.org/10.1111/1348-0421.12079. (PMID: 10.1111/1348-0421.1207923822120) Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza a vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157–1163. https://doi.org/10.1038/13484. (PMID: 10.1038/1348410502819) Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, Limlamthong Y, Fenner BJ, Spencer L, Kwang J (2006) Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol 6:16. https://doi.org/10.1186/1471-2180-6-16. (PMID: 10.1186/1471-2180-6-16165041081397843) OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (2016) Equine Influenza, Chap. 2.5.7. Paris: OIE. http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.05.07_EQ_INF.pdf. Oladunni FS, Oseni SO, Martinez-Sobrido L, Chambers TM (2021) Equine influenza virus and vaccines. Viruses 13:1657. https://doi.org/10.3390/v13081657. Olsen CW, McGregor MW, Dybdahl-Sissoko N, Schram BR, Nelson KM, Lunn DP, Macklin MD, Swain WF, Hinshaw VS (1997) Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice. Vaccine 15:1149–1156. https://doi.org/10.1016/S0264-410X(96)00309-X. (PMID: 10.1016/S0264-410X(96)00309-X9269061) Osterholm MT (2005) Preparing for the next pandemic. N Engl J Med 352:1839–1842. https://doi.org/10.1056/NEJMp058068. (PMID: 10.1056/NEJMp05806815872196) Paillot R, Prowse L (2012) ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse. Vet Immunol Immunop 145:516–521. https://doi.org/10.1016/j.vetimm.2011.11.019. (PMID: 10.1016/j.vetimm.2011.11.019) Park EH, Song BM, Yum J, Kim JA, Oh SK, Kim HS, Cho GJ, Seo SH (2014) Protective efficacy of a single dose of baculovirus hemagglutinin-based vaccine in chickens and ducks against homologous and heterologous H5N1 virus infections. Viral Immunol 27:449–462. https://doi.org/10.1089/vim.2014.0029. (PMID: 10.1089/vim.2014.0029252116404217023) Pavulraj S, Bera BC, Joshi A, Anand T, Virmani M, Vaid RK, Shanmugasundaram K, Gulati BR, Rajukumar K, Singh R, Misri J (2015) Pathology of Equine Influenza virus (H3N8) in Murine Model. PloS one 10: 143094. https://doi.org/10.1371/journal.pone.0143094 . eCollection 2015. Pavulraj S, Virmani N, Bera BC, Joshi A, Anand T, Virmani M, Singh R, Singh RK, Tripathi BN (2017) Immunogenicity and protective efficacy of inactivated equine influenza (H3N8) virus vaccine in murine model. Vet Microbio 210:188–196. https://doi.org/10.1016/j.vetmic.2017.08.013. (PMID: 10.1016/j.vetmic.2017.08.013) Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W (2021) Immunogenicity of Calvenza-03 EIV/EHV((R)) Vaccine in Horses: Comparative In Vivo Study. Vaccines (Basel), 9. https://doi.org/10.3390/vaccines9020166. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Disc 6:404–414. https://doi.org/10.1038/nrd2224. (PMID: 10.1038/nrd2224) Qi T, Guo W, Huang WQ, Li HM, Zhao L-P, Dai L-L, He N, Hao X-F, Xiang W-H (2010) Genetic evolution of equine influenza viruses isolated in China. Arch Virol 155:1425–1432. https://doi.org/10.1007/s00705-010-0724-y. (PMID: 10.1007/s00705-010-0724-y20559670) Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493–497. (PMID: 10.1093/oxfordjournals.aje.a118408) Santiago FW, Emo KL, Fitzgerald T, Treanor JJ, Topham DJ (2012) Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems. Vaccine 30:4606–4616. https://doi.org/10.1016/j.vaccine.2012.05.005. (PMID: 10.1016/j.vaccine.2012.05.005226090353379008) Sathaliyawala T, Rao M, Maclean DM, Birx DL, Alving CR, Rao VB (2006) Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol 80:7688–7698. https://doi.org/10.1128/JVI.00235-06. (PMID: 10.1128/JVI.00235-06168403471563720) Sguazza GH, Fuentealba NA, Tizzano MA, Galosi CM, Pecoraro MR (2013) Expression of the hemagglutinin HA1 subunit of the equine influenza virus using a baculovirus expression system. Rev Argent Microbiol 45:222–228. https://doi.org/10.1016/S0325-7541(13)70028-2. (PMID: 10.1016/S0325-7541(13)70028-224401775) Sheridan C (2004) Next generation flu vaccine boosted by Chiron debacle. Nat Biotechnol 22:1487–1488. https://doi.org/10.1038/nbt1204-1487. (PMID: 10.1038/nbt1204-148715583640) Spellberg B, Edwards JE Jr (2001) Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 32:76–102. https://doi.org/10.1086/317537. (PMID: 10.1086/31753711118387) Szyszko E, Brokstad K, Cox RJ, Hovden AO, Madhun A, Haaheim LR (2006) Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol 64:467–475. https://doi.org/10.1111/j.1365-3083.2006.01805.x. (PMID: 10.1111/j.1365-3083.2006.01805.x17032238) Tabynov K, Kydyrbayev Z, Ryskeldinova S, Assanzhanova N, Sansyzbay A (2014) Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza. Vaccine 32:2965–2971. https://doi.org/10.1016/j.vaccine.2014.03.095. (PMID: 10.1016/j.vaccine.2014.03.09524726250) Thomas PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12:48. (PMID: 10.3201/eid1201.051237164947173291410) Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O’Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732–1737. https://doi.org/10.1016/S0264-410X(00)00395-9. (PMID: 10.1016/S0264-410X(00)00395-911166898) Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M (2007) Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297:1577–1582. https://doi.org/10.1001/jama.297.14.1577. (PMID: 10.1001/jama.297.14.157717426277) Ulivieri C, Citro A, Ivaldi F, Mascolo D, Ghittoni R, Fanigliulo D, Manca F, Baldari CT, Pira GL, Del Pozzo G (2008) Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides. Immunol Lett 119:62–70. https://doi.org/10.2174/0929867324666170911160426. (PMID: 10.2174/092986732466617091116042618538862) Virmani N, Bera BC, Singh BK, Shanmugasundaram K, Gulati BR, Barua S, Vaid RK, Gupta AK, Singh RK (2010) Equine influenza outbreak in India (2008–09): Virus isolation, sero-epidemiology and phylogenetic analysis of HA gene. Vet Microbiol 143:224–237. https://doi.org/10.1016/j.vetmic.2009.12.007. (PMID: 10.1016/j.vetmic.2009.12.00720053509) Wiley DC, Skehel JJ (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56:365–394. https://doi.org/10.1146/annurev.bi.56.070187.002053. (PMID: 10.1146/annurev.bi.56.070187.0020533304138) Yang H, Carney P, Stevens J (2010) Structure and receptor binding properties of a pandemic H1N1 virus hemagglutinin. PLoS Curr 22:2. https://doi.org/10.1371/currents.RRN1152. (PMID: 10.1371/currents.RRN1152) Yang E, Cho Y, Choi JA, Choi Y, Park PG, Park E, Lee CH, Lee H, Kim J, Lee JM, Song M (2015) Protection of mice against pandemic H1N1 influenza virus challenge after immunization with baculovirus-expressed stabilizing peptide fusion hemagglutinin protein. JMB 25:280–287. https://doi.org/10.4014/jmb.1410.10035. (PMID: 10.4014/jmb.1410.10035) Yang ML, Wang CT, Yang SJ, Leu CH, Chen SH, Wu CL, Shiau AL (2017) IL-6 ameliorates acute lung injury in influenza virus infection. Sci Rep 7:43829. https://doi.org/10.1038/srep43829. (PMID: 10.1038/srep43829282627425338329) Yondon M, Heil GL, Burks JP, Zayat B, Waltzek TB, Jamiyan BO, McKenzie PP, Krueger WS, Friary JA, Gray GC (2013) Isolation and characterization of H 3 N 8 equine influenza a virus associated with the 2011 epizootic in Mongolia. Influenza Other Respir Viruses 7:659–665. https://doi.org/10.1111/irv.12069. (PMID: 10.1111/irv.12069232894273626732) Yousefi A, Fotouhi F, Hosseinzadeh S, Kheiri MT, Farahmand B, Montazeri S, Mousavi F (2012) Expression of antigenic determinants of the haemagglutinin large subunit of novel influenza virus in insect cells. Folia Biol 58:151–156.
فهرسة مساهمة:	Keywords: Equine influenza virus; Haculovirus expression system bacteriophage; Haemagglutinin; Immunogenicity; Vaccine
المشرفين على المادة:	0 (Influenza Vaccines) 0 (Vaccines, Subunit) 0 (Hemagglutinin Glycoproteins, Influenza Virus)
تواريخ الأحداث:	Date Created: 20240326 Date Completed: 20240603 Latest Revision: 20240603
رمز التحديث:	20240603
DOI:	10.1007/s11259-024-10356-6
PMID:	38528300
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1573-7446
DOI:	10.1007/s11259-024-10356-6